HR6423-119

In Committee

HELP Copays Act

119th Congress Introduced Dec 4, 2025

Summary

What This Bill Does

The HELP Copays Act changes how health plans treat third-party assistance for patient cost sharing. It amends the Public Health Service Act summary-of-benefits standards so deductibles, coinsurance, copayments, and out-of-pocket limits include amounts paid by or on behalf of an enrolled individual, including nonprofit financial assistance and prescription drug manufacturer assistance. It makes parallel changes to Affordable Care Act annual cost-sharing limit rules so those assistance amounts count toward deductibles, coinsurance, copayments, similar charges, and other covered expenditures. It also applies the cost-sharing limitation to prescription drugs as if the reference to essential health benefits covered any item or service within the prescription drug category. Finally, it creates a tax-code safe harbor so, for plan years beginning after December 31, 2025, certain amounts applied to deductibles do not cause a high deductible health plan to lose HDHP status.

Who Benefits and How

Patients using manufacturer copay assistance or nonprofit assistance benefit because those payments would count toward deductibles and out-of-pocket limits instead of being excluded by accumulator policies. People with high-cost prescription drugs benefit most directly because assistance can help them reach cost-sharing limits sooner. Nonprofit assistance organizations and drug manufacturers benefit because their assistance more directly reduces patient cost-sharing obligations. Employers and plan sponsors that want HDHP-compatible assistance rules benefit from the tax-code safe harbor.

Who Bears the Burden and How

Group health plans and health insurance issuers must count third-party assistance toward cost-sharing obligations and may face higher plan costs when patients reach deductibles or out-of-pocket maximums sooner. Pharmacy benefit managers and accumulator vendors may need to change benefit designs. Federal health and tax administrators must update standards, cost-sharing rules, and HDHP safe-harbor guidance. Premiums could rise if plans absorb more prescription drug cost sharing.

Key Provisions

  • Amends Public Health Service Act standards so deductibles, coinsurance, copayments, and out-of-pocket limits include third-party assistance.
  • Amends ACA cost-sharing limit rules to count nonprofit and manufacturer financial assistance toward patient obligations.
  • Applies annual cost-sharing limits to covered prescription drugs in the prescription drug essential health benefit category.
  • Creates an HDHP safe harbor for certain assistance applied to deductibles after December 31, 2025.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Requires health plans and insurers to count third-party financial assistance from nonprofits or drug manufacturers toward deductibles, copayments, coinsurance, and out-of-pocket limits, extends cost-sharing limits to covered prescription drugs, and preserves HDHP treatment for certain assistance after 2025.

Key Policy Areas

Health Care, Insurance, Pharmaceuticals, Tax

Primary Purpose

Requires health plans and insurers to count third-party financial assistance from nonprofits or drug manufacturers toward deductibles, copayments, coinsurance, and out-of-pocket limits, extends cost-sharing limits to covered prescription drugs, and preserves HDHP treatment for certain assistance after 2025.

Policy Domains

Health Care Insurance Pharmaceuticals Tax

Substantive provisions

Identified Gains
  • Patients using copay assistance
  • People using high-cost prescription drugs
  • Nonprofit assistance organizations
  • Prescription drug manufacturers
  • Employers offering HDHPs
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
Employers offering HDHPs:
Patients using copay assistance:
Prescription drug manufacturers:
Nonprofit assistance organizations:
People using high-cost prescription drugs:
Identified Costs
  • Group health plans
  • Health insurance issuers
  • Pharmacy benefit managers
  • Accumulator vendors
  • Federal health administrators
  • Federal tax administrators
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
Group health plans:
Accumulator vendors:
Health insurance issuers:
Pharmacy benefit managers:
Federal tax administrators:
Federal health administrators:

Legislative Progress

In Committee
Introduced Committee Passed
Dec 4, 2025

Mr. Kean (for himself, Ms. Barragán, Mrs. Miller-Meeks, Mr. Auchincloss, …

Dec 4, 2025

Referred to the Committee on Energy and Commerce, and in …

Dec 4, 2025

Introduced in House

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Healthcare
3 mentions across 1 clause
+2 positive -1 negative

Patients using copay assistance, People using high-cost drugs, Pharmacy benefit managers

Positive-direction: Patients using copay assistance, People using high-cost drugs

Negative-direction: Pharmacy benefit managers

Financial Services
2 mentions across 1 clause
-2 negative

Group health plans, Health insurance issuers

Government
2 mentions across 1 clause
-2 negative

Federal health administrators, Federal tax administrators

Non-Profit Institutions
1 mention across 1 clause
+1 positive

Nonprofit assistance organizations

Pharmaceuticals
1 mention across 1 clause
+1 positive

Prescription drug manufacturers

1/2
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Health Care Insurance Pharmaceuticals Tax

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology